General
Preferred name
APREMILAST
Synonyms
CC-10004 ()
Apremilast (CC 10004) ()
Apremilast (CC-10004) ()
CC10004 ()
Otezla ()
Apremilast-d5 ()
P&D ID
PD009329
CAS
608141-41-9
1258597-47-5
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
2014
Drug Status
investigational
approved
Drug indication
Psoriasis vulgaris
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
DEPRESSION AND SUICIDE: Apremilast has been associated with increased depression and suicidal behaviour in patients. ; WEIGHT LOSS: Apremilast has been associated with weight decrease in patients.
DESCRIPTION
Apremilast is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor (additional comment in ). It is selective for PDE4 over other PDE isozymes, but non-selective over PDE4 isoforms .
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
24
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
41
Molecular Weight
460.13
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
2
cLogP
2.43
TPSA
119.08
Fraction CSP3
0.32
Chiral centers
1.0
Largest ring
6.0
QED
0.6
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Apoptosis
Metabolic Enzyme/Protease
Target
PDE4
PDE4A, PDE4B, PDE4C, PDE4D
PDE4 inhibitor
Phosphodiesterase (PDE)
TNF Receptor
PDE,TNF-alpha
Indication
psoriasis, psoriatic arthritis
Disease Area
dermatology, rheumatology
MOA
phosphodiesterase inhibitor
Source data
